OvaScience Inc., which develops fertility treatments, rose 5.5 percent after saying one of its procedures improved clinical pregnancy rates in women for whom in vitro fertilization previously failed.
The Cambridge, Massachusetts-based company jumped $1.52 to $29.17, a three-week high, at the close in New York. The stock has fallen 45 percent since a peak on March 24.
Pregnancy rates improved for women using an OvaScience treatment called Augment, which tries to fortify eggs for embryo development with cell structures from the ovary lining, according to the company.
“The increased pregnancy rates with the Augment treatment, which showed at least a three-fold increase over these women’s prior histories, are promising, particularly because they have historically had poor prognoses with multiple failed IVF cycles and other fertility risk factors,” said Robert Casper, medical director of TCART Fertility Partners of Toronto, in a presentation quoted in a company statement. Casper presented on his clinical experience with the treatment and was referring to In Vitro Fertilization.
Casper said that for 34 women undergoing the treatment, the clinical pregnancy rates rose by three to four times with nine ongoing pregnancies and a healthy birth. A report released in March was met with skepticism from academics doubting the validity of company data. The Augment treatment isn’t available in the U.S.
(A previous version of this story corrects the company name in third paragraph.)